Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Phase 1 Completed 12 enrolled Mannkind Corporation

RandomizedSingle-groupOpen-labelTreatment

Summary

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

Timeline

Start: 2007-02
Primary completion: 2009-09
Completion: 2009-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PSMA/PRAME	Unknown	—	—

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Summary

Timeline

Drugs

Indications